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1. Introduction 
Thyroid cancer (TC) has a much lower incidence (0.74% in men, 2.3% in women worldwide) 
than cancers of breast, colon, prostate, lung and endometrium but is the seventh most 
frequent human malignancy and the most common neoplasm of the endocrine system. 
Thyroid cancer accounts for 1% of all newly diagnosed cancer cases. Over the past decades 
the incidence of thyroid cancer has increased significantly (50% in the last 25 years). It is 
suspected that the observed increase is mainly due to better detection methods because 
microcarcinoma are seen frequently (up to 35%) in autopsies (Harach et al., 1985). Most 
cancers of the thyroid originate from follicular thyrocytes, only a minority of cancers, 
namely medullary thyroid cancer, originate from calcitonin producing C-cells (C-cells). They 
belong to another entity of tumors and will not be addressed in this review. 
Carcinomas of follicular cell origin include well-differentiated and poorly differentiated 
thyroid cancers (DTC) and anaplastic thyroid cancers. DTC comprises papillary thyroid 
carcinoma (PTC), which accounts for 80-90% of all thyroid cancer cases, follicular thyroid 
carcinoma (FTC) and Hürthle cell tumors. Undifferentiated/anaplastic thyroid cancer (ATC) 
is rare and accounts for only 1-2% of all TC. 
The prognosis of DTC is good with a 10-year survival rate of 85% (Eustatia-Rutten et al., 
2006). Recurrence, however, occurs in up to 30% of patients and only 30% of patients with 
distant metastases respond to radioiodine therapy with complete remission (Dohan et al., 
2003). A total of 10-20% of patients develop distant metastases (Durante et al., 2006). In this 
group the 10-year survival rate drops to 40%. ATC usually has a fatal outcome.  
2. Current treatment of thyroid carcinoma 
The standard treatment of well-differentiated TC is surgery followed by radioiodine 
remnant ablation. As only thyrocytes are taking up iodide to a reasonable degree, 
radioiodine treatment is very specific and has a low rate of adverse effects. In case of 
insufficient iodine uptake options are few and survival is poor. External beam radiation is 
used as a palliative therapeutic option but these tumors usually are not responsive to this 
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therapy. Adriamycin is the only cytostatic drug approved by the FDA for treatment of 
radioiodine refractory thyroid carcinoma. ATC do not express thyrotropin receptors; they 
neither take up iodide nor produce thyroglobulin. Surgical resection is only recommended 
for localized disease, which is rarely the case. In the advanced stage patients do not profit 
from removal of the tumor mass. Palliation to improve survival includes tracheotomy, 
radiation and chemotherapy or a combination of the three treatments.  
Tyrosine kinase inhibitors, PPAR-y activators, retinoids, bortezomib, galdanomycin, VEGF 
receptor antagonists, stimulation of antigen presenting dendritic cells and p53 gene therapy 
are not yet approved for treatment of metastatic thyroid cancer and reserved for patients 
with life-threatening disease.  
This review focuses on re-differentiation as mode of therapeutic action. Tyrosine kinase 
inhibitors, which target general tumor features like proliferation and apoptosis, currently 
represent the most promising group of compounds for the treatment of radioiodine-
refractive TC. Their mode of action and the most promising candidates will be shortly 
addressed. 
3. Targeted therapy  
3.1 Definition and types of targeted therapies  
Targeted therapies interfere with a specific molecular target, which has a critical role in 
tumor growth and progression. For targeted therapies antisense drugs, monoclonal 
antibodies and small molecules may be used. Targeted therapies, which intend to remove a 
block in normal cell differentiation, are termed ‘differentiation therapy’.  
The following molecules are involved in transformation and progression of TC and are, 
therefore, used in drug development for targeted therapies (Table 1).  
3.2 Tyrosine Kinase Inhibitors (TKI) 
Receptors over-expressed in cancer cells stimulate cell growth and proliferation through a 
cascade of tyrosine kinases (TKs) (Figure 2). TKIs may either compete with the ligand by 
binding to the extracellular domain or they may bind to the ATP-binding site of the kinase. 
Examples for ligand analogues are monoclonal antibodies like the anti-human epidermal 
growth factor receptor 2 antibody Herceptin® (trastuzumab), which is very successful in the 
treatment of breast cancer. By contrast, anti-EGFR antibodies show no significant anti-tumor 
action in PTC cell lines (Gabler et al., 1997).  
Small molecule inhibitors, also called ATP mimetics, hinder the binding of ATP to the ATP 
binding pocket of protein kinases. Other compounds bind to the substrate-binding domain. 
By this binding autophosphorylation and signal transduction is inhibited. TKIs can inhibit 
proliferation and induce cell differentiation and apoptosis. As the catalytic domain of the 
TKs is very similar, most TKIs are not specific for one growth factor.  
The most promising TKIs are briefly mentioned in the following section. For more 
information, the reader is referred to one of the more recent reviews (e.g. Coelho et al., 2007; 
Ho & Sherman, 2011; Kapiteijn et al., 2011).  
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Molecular 
target 
Function Role in TC
VEGF Neo-angiogenesis Increased expression in TC  
(Soh et al., 1997)
RET oncogene Receptor for ligands of the glial-
derived neurotropic factor family  
Trigger for autophosphorylation 
and intracellular signalling with 
stimulation of Ras/ERK/and 
PI3kinase/V-Akt cascade 
In PTC chromosomal inversions and 
recombinations cause chimeric 
RET/PTC sequences, which are found 
in around 30% of thyroid carcinoma 
(Rabes et al., 2000). RET/PTC is 
frequently seen in microcarcinoma 
suggesting a role in the early phase of 
tumorigenesis.
c-Met Proto-oncogene and receptor for 
hepatic growth factor, important 
for cell migration, proliferation, 
differentiation and angiogenesis.
It is over-expressed in 70% of PTC  
(Di Renzo et al., 1992). EGFR, RAS and 
RET regulate its expression. 
BRAF Member of the RAF familiy of 
serine/threonine kinases and are 
components of the RAF-MAPK 
kinase-ERK (RAF-MEK-ERK) 
intracellular signalling pathway 
Point mutations seen in about 44% of 
PTCs and mutations are associated 
with a more and more aggressive 
phenotype. BRAF mutations are 
associated with impairment of NIS 
causing resistance to radioiodine 
uptake (Riesco-Eizaguirre et al., 2006; 
Romei et al., 2008). 
Hsp90 Multichaperone heat shock protein, 
which mediates maturation and 
stability of several proteins 
involved in oncogenesis like  
EGF-R, Her-2, Akt, BRAF,  
CRAF, p53 
mRNA expression of Hsp90 correlated 
to aggressive biological behaviour in 
TC (Boltze et al., 2003) 
RAS GTP-binding protein involved in 
proliferation, differentiation and 
cell survival. Ras acts via 
phosphatidyl inositol-3–phosphate 
kinase (PI3K) and through 
mitogen-activated protein kinase 
(MEK) and extracellular signal 
regulated kinases (ERKs). 
Ras mutations in H-,N- and K-Ras 
oncogenes are common in TC and 
appear to be an early event in FTC 
tumorigenesis and are reported in 
about 50% of FTCs (Lemoine et al., 
1989). 
Farnesyltrans-
ferase 
Anchor of RAS in the plasma 
membrane. This anchorage is 
necessary for activation of RAS.  
Involved in the activation of p21 (ras) 
in thyrocytes (Laezza et al., 1998) 
MEK 
(MAPK/Erk 
kinase) 
Key mediator in growth-promoting 
signals. 
This kinase plays an important role in 
the pathogenesis of TC (Fagin, 2004) 
EGFR (Her1, 
ErbB1) 
Member of the Erb family of 
receptors and abnormally regulated 
in many cancer types. In addition 
Overexpression is correlated to the 
presence of metastases in TC 
(Rodriguez-Antona et al., 2010). 
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Molecular 
target 
Function Role in TC
to EGFR also ErbB2 (Her2/neu) is 
involved in the pathology of TC. 
EGFR tyrosine kinase activates Ras-
Raf-MAPK cascade and the PI3K 
pathway. 
PI3K Mediator of signals from many 
receptor tyrosine kinases.  
 
Mutations and amplifications of PI3K 
have been described in differentiated 
and anaplastic primary tumors (Hou 
et al., 2007). Mutations in 
phosphoinositide-3-kinase alpha 
polypeptide and in Akt1 protein 
appear to be indicators for more 
aggressive, radioiodine refractory TC 
(Ricarte-Filho et al., 2009). 
Mammalian 
target of 
rapamycin 
(mTOR) 
Serine/threonine kinase, which 
serves as a downstream mediator 
of growth factors. 
In thyrocytes, mTOR is also activated 
independent from Akt by direct 
stimulation through TSH (Brewer et 
al., 2007) and it may be suggested that 
mTOR is an especially useful target for 
the treatment of TC.  
Akt/protein 
kinase B 
Important mediator in apoptosis, 
proliferation and cell cycle 
progression. 
Its expression is increased in sporadic 
FTC (Ringel et al., 2001). 
 
Table 1. Overview on established targets for targeted therapies 
3.2.1 Non thyroid specific targets: Neoangiogenesis  
Strategies to reduce/inhibit angiogenesis include inhibition of VEGF signalling, where 
several TKIs showed efficacy in thyroid cancer. Although Sutinimib® (SU11248), Motesanib 
diphosphate (AMG-706) and Pazopanib (Votrient®, GW-786034) also inhibit other TKs, it is 
postulated that the therapeutic effect is caused mainly by inhibition of VEGF signalling. 
These compounds and the selective VEGF-R inhibitor Axitinib® (AG-013736) induced 
stable disease as best response in 42%-67% of the patients. Inhibition of angiogenesis is also 
the target for other compounds like thalidomide (Thalidomid®) and lenalidomide 
(Revlimid®, CC-5013), which achieved stable disease in clinical trials. The prodrug 
Combre(ta)statin A4 phosphate binds to tubulin and destabilizes tumor blood vessels. In 
trials with ATC the compound induced stable disease in 30% of the patients. 
3.2.2 Non thyroid specific targets: Proliferation and apoptosis 
The BRAF inhibitor Nexavar® (Sorafenib) (BAY 43-9006) has been tested in patients with 
radioiodine refractory TC. Although no iodine uptake was seen, partial responses and stable 
disease have been reported. XL281, a pan RAF inhibitor, induced stable disease in PTC 
patients. AZD6244 (ARRY142886, Selumetinib), a MEK1 and MEK2 inhibitor, showed  
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 : growth factor like VEGF, EGF, HGF,  : H-Ras; : GTP; : phosphate residue; : 
domain for kinase activity 
Fig. 1. Activation of growth receptor TKs. 1: ligand binds to the receptor. Receptor 
dimerization and receptor binding to adapter protein, Grb2, coupled to the guanine 
nucleotide releasing factor, Son of Sevenless (SOS), occurs. Dimerization of the receptor 
leads to activation of Akt/PKB (7) and to activation of Ras (2a). Activation of Raf also needs 
anchorage of the Ras-GTP complex to the plasma membrane by farnesyltransferase (2b). Ras 
signalling acts through activation of Raf (3), MEK (4), ERK1/2 (5) that translocates into the 
nucleus (N) and acts (6) on transcription. Akt/PKB is activated by HSP90 (10) and 
stimulates through mTOR activation (8) transcription in the nucleus (9). 
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similar efficacy in the first studies but was ineffective in the most recent phase II trial on 
iodine refractory thyroid cancer. Zelborat® (PLX 4032 (RG7204, RO5185426, Vemurafenib) 
is an inhibitor of only mutated BRAF showing prolonged stable disease in a small phase I 
study. Stable disease was also obtained in a clinical trial with the EGFR inhibitor Iressa® 
(Gefitinib, ZD1939) in advanced thyroid cancers not amenable for surgery and/or RAI 
therapy. The authors explained the limited success of the drug by the fact that EGFR 
inhibitors, including Gefitinib, are ineffective in tumors with Raf mutations. Clinical trials 
on other TKIs like for instance the multi-kinase inhibitors E7080 (Lenvatinib[USAN]) and 
AMG706 (Motesanib diphosphate) are ongoing (www.clinicaltrials.gov). 
Out of the several inhibitors of Hsp90, the ligand of c-Met, which have been tested in-vitro 
only 17-allylamino-17-demethoxygeldanamycin (17-AAG) appeared to be potent enough to 
justify phase I/II clinical trial in TC. The farnesyltransferase inhibitors BMS-214662 and 
L744832 have been evaluated in clinical phase I trials including thyroid carcinoma patients 
and no improvement in survival was reported. Results of a phase II trial with a combination 
of Everolimus Zortress®, Afinitor® (RAD001), an inhibitor of mTOR and sorafenib are 
pending.  
The antiproliferative therapy with the COX-inhibitor Celebrex® (celecoxib) was not 
successful in TC.  
Meta-analysis in a phase II trial on Velcade® (bortezomib) achieved mainly stable disease in 
metastased DTC, but due to increased Tg levels, efficacy is not certain. The compound 
displays antitumor effects also in cell lines from ATC.  
JNJ-26854165, which inhibits the ubiquitin protein ligase HDM2, prevents the degradation 
of the tumor suppressor p53, and showed moderate success rates in patients with 
progressive Hurthle cell carcinoma. 
Some of these TKIs act also as differentiating agents: 17-AAG increases the accumulation of 
iodide by decreasing its efflux, whereas NIS localization and amount are not changed 
(Marsee et al., 2004; Elisei et al., 2006). The MEK inhibitor PD98059, a flavonoid, increases 
NIS protein, but not iodide uptake (Vadysirisack et al., 2007). As surface expression was not 
decreased, it is suspected that a lower Vmax decreased the turnover rate of iodide. The 
mTOR inhibitor Rapamune® (sirolimus) increased iodide uptake in rat thyrocytes (de 
Souza et al., 2010).  
4. Re-differentiation therapy: Thyroid-specific targets 
Re-differentiation intends to reverse changes, which occurred during transformation of the 
cells. Proteins involved in thyroid hormone synthesis include sodium-iodide symporter 
(NIS), thyroperoxidase (TPO), pendrin (PDS) and thyroglobulin (Tg).  
For the synthesis of the thyroid hormones triiodothyronine (T3) and thyroxine (T4), iodide is 
taken up from the blood stream by NIS localized at the basal side of the thyrocyte (Figure 2). 
Iodide is concentrated 20-40 fold with respect to the plasma concentration by NIS, the 
uptake is active and iodide is translocated towards the colloid by iodide efflux mediated 
mainly by PDS. Thyroglobulin is produced in the endoplasmic reticulum and Golgi 
apparatus and secreted in the follicular lumen. At the cell-colloid interface iodide is coupled 
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to specific tyrosyl residues in thyroglobulin by the integral membrane protein TPO and 
monoiodotyrosine and diiodotyrosine is formed. Hydrogen peroxide for the oxidation of 
iodide by TPO is provided by the thyroid dual oxidase (DuOx). TPO also catalyzes the 
integration of hormone residues (coupling of iodotyrosines) in Tg. Excess hydrogen peroxide 
(H2O2) not involved in the oxidation of iodide may act mutagenic or carcinogenic. Selen-
containing glutathione peroxidase is therefore typically upregulated to provide protection 
from oxidative damage. Some glutathione peroxidase gene polymorphisms are linked to an 
increased risk effect for TC presumably by lack of detoxification of hydrogen peroxide. Upon 
demand for thyroid hormones, endocytosis of iodinated Tg occurs. Iodinated Tg is hydrolysed 
in lysosomes and the hormones T3 and T4 secreted into the blood stream.  
 
Fig. 2. Schematic drawing illustrating the synthesis of thyroid hormone in the thyroid gland 
and ultrastructure of a follicle cell. Iodide is taken up into the thyrocyte by NIS and Tg is 
synthetized from amino acids at the endoplasmic reticulum and the Golgi apparatus and 
transported in vesicles to the follicular lumen. PDS transports iodide into the lumen and 
TPO integrates iodide into Tg and couples iodotyrosines to hormone residues. The protein 
machinery for the synthesis of Tg, endoplasmic reticulum (ER), Golgi apparatus (G) as well 
as apical microvilli, tight junctions (arrowheads) and mitochondria (M) are clearly seen in 
the ultrastructure. N: nucleus, EC: endothelial cell.  
In DTC NIS is expressed at different levels and pendrin expression is usually absent. TPO is 
expressed at low levels in FTC and follicular variants of PTC but below the detection limit in 
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PTC. The H2O2 generation system is present in DTC and levels increased in PTC. The TSH-R 
is present in most DTC. The capacity to synthesize iodinated and thyroxine rich Tg is lost in 
FTC due to defect in NIS and in PTC due to altered apical iodide transport and TPO activity 
(Gerard et al., 2003).  
4.1 Sodium-iodide symporter (NIS) 
NIS is an integral plasma membrane glycoprotein, which transports two sodium ions along 
with one iodide ion. The transmembrane gradient of sodium serves as the driving force for 
iodide uptake. The mature NIS protein has 13 transmembrane regions, the N-terminus is 
facing the extracellular milieu and the C-terminus is directed towards the intracellular 
milieu. Glycosylation occurs at three sites in the protein, but does influence neither stability 
nor membrane targeting. Phosphorylation occurs at the C-terminus. Affinity of NIS is higher 
for perchlorate and rhenium oxide than for iodide. 
NIS is not only expressed in the thyroid but also in salivary gland, choroid plexus, gastric 
mucosa, lactating mammary gland and ciliary body of the eye. Potential expression of the 
protein has also been shown in colon, kidney, pancreas, rectum, thymus, placenta and non-
lactating mammary gland (Wapnir et al., 2003). mRNA has been detected in almost all 
tissues but RT-PCR yields a large number of false positive results because of its high 
sensitivity (Dohan et al., 2003). 
4.1.1 Regulation of NIS in the normal thyroid  
TSH acts both on NIS transcription and on targeting of NIS to the plasma membrane 
through increase of c-AMP levels. The NIS promoter contains two important regions: (a) the 
proximal NIS promotor, where thyroid transcription factor-1, NIS-TSH-responsive factor-1 
and Specificity protein 1 (Sp-1) bind and (b) the NIS upstream enhancer with binding sites 
for the paired domain factor Pax-1, thyroid transcription factor-1 and c-AMP-responsive 
element like sequences. The interaction of c-AMP-responsive element like sequences with 
Pax-1 is necessary for transcription of NIS. The localization to the plasma membrane 
appears to be mainly caused by binding of protein-recognition PDZ target motif at the 
carboxyl-terminus of the protein to PDZ-binding proteins, not by phosphorylation. TSH also 
regulates half-life of NIS: in the presence of TSH it is 5 days, in the absence 3 days (Riedel et 
al., 2001).  
Cytokines like tumor necrosis factor , interferon-, interleukin (IL)-1, IL-1 and IL-6 
inhibit NIS mRNA expression and iodide uptake. This inhibition may be the cause of 
hypothyroidism in autoimmune processes.  
Tumor necrosis factor  in addition to decreasing TSH-induced NIS expression also changes 
the morphology of thyroid cells from cuboidal to flattened phenotype.  
Estradiol down-regulates NIS expression and thereby may contribute to the higher 
incidence of goiter in women.  
High intracellular iodide concentration down-regulates NIS. Similarly, follicular Tg acts as a 
potent suppressor of all thyroid-specific genes. This inhibition may represent a negative 
feedback autoregulatory mechanism and corresponds to the morphological heterogeneity of 
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thyroid follicles: the active follicles display a cuboidal epithelium with high NIS expression 
and little Tg in the lumen, inactive follicles show a flattened epithelium, low or absent NIS 
expression and much Tg in the lumen. 
High extracellular concentrations of iodide decrease the function of NIS, in addition to other 
effects. This phenomenon is called Wolff-Chaikoff effect (Wolff & Chaikoff, 1948). Although, 
the effect has been known for many years, its mechanism is still not well understood; 
transcriptional and post-transcriptional changes are involved. 
4.1.2 NIS in thyroid cancer 
NIS in thyroid cancer is not mutated (Russo et al., 2001), and various groups reported the 
amount of mRNA, compared to normal tissue, differently. As NIS protein is regulated at 
different levels (transcriptional, translational, posttranslational, targeting and intracellular 
distribution) the detection of mRNA is poorly predictive for normal function. NIS protein 
levels in thyroid cancer were reported to be higher than in normal tissue by some groups 
and lower than normal by others (Arturi et al., 1998; Saito et al., 1998; Lazar et al., 1999; Park 
et al., 2000). Impaired iodide uptake can be caused by absent or decreased NIS expression 
and by impaired targeting and insufficient retention at the plasma membrane. In the largest 
study on tissue, overexpression in combination with intracellular localization was seen in 
70% of the TC samples (Dohan et al., 2001). Plasma membrane localization was rare and 
often not polarized but present at the apical and basal membrane. It is presumed that the 
altered trafficking of NIS causes NIS dysfunction. The pathological localization of NIS may 
also be induced by binding to the proto-oncogene pituitary tumor-transforming gene 
binding factor (PBF). Overexpression of this factor is associated with aggressive behaviour 
of TC. PBF binds to NIS, alters its subcellular localization and, thereby, inhibits its ability to 
take up iodide (Smith et al., 2009). Paired mRNA and protein analysis showed that 
decreased mRNA levels were associated with increased cytoplasmic staining of NIS (Wang 
et al., 2011). It was also suggested that NIS protein in cancer tissue is immature and has an 
abnormal turn-over rate (Saito et al., 1998, Dohan et al., 2001). 
Intracellular NIS can cause negative feed-back on NIS mRNA synthesis. Reduced TSH-R 
may also cause low NIS mRNA levels and deficient NIS migration (Sodre et al., 2008). 
Activation of BRAF, Ras and RET decrease NIS mRNA. BRAF, in addition, also impairs 
targeting of NIS to the plasma membrane (Riesco-Eizaguirre et al., 2006). 
4.2 Pendrin (PDS) 
Pendrin is a transmembrane glycoprotein with three putative extracellular glycosylation 
sites on asparagine-residues. Both C- terminus and N-terminus are located inside the cytosol 
and contain a sulphate transporter/antisigma factor antagonist domain (Royaux et al., 2000). 
PDS was identified as the most important transporter for iodide export but its unique role is 
questioned because patients with biallelic mutation display only mild thyroid symptoms 
and PDS knock-out mice do not develop goiter (Wolff, 2005). On the other hand, TSH 
stimulates iodide transport across the apical membrane (Nilsson et al., 1990) and induces a 
rapid translocation of PDS from endosomes to the plasma membrane (Kopp et al., 2008) 
suggesting a causative link between translocation and iodide metabolism. Efflux by an 
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additional transporter is hypothesized: the formerly named apical iodide transporter (AIT), 
which has been re-named to sodium/monocarboxylate transporter (SMCT), has been 
removed from the list of potential candidates (Paroder et al., 2006).  
Extrathyroidal expression of PDS is more restricted than that of NIS. Expression has been 
detected in kidney, Sertoli cells, inner ear, mammary gland and placenta (Lacroix et al., 
2001; Wangemann et al., 2004)  
PTCs without iodide uptake have slightly reduced NIS and significantly reduced Tg, TPO 
and PDS levels (Mian et al., 2008). This shows that loss in iodide uptake depends not only 
on NIS function but also on other molecules in the intracellular thyroid metabolism. 
Together with NIS, PDS and Tg, TPO expression is decreased in PTC with BRAF mutation 
(Durante et al., 2007).  
4.3 Thyroperoxidase (TPO) 
TPO is a glycosylated transmembrane hemoprotein, which uses H2O2 as cofactor and 
catalyses the oxidation of iodide to iodines and the attachment of oxidized iodines to certain 
tyrosine residues on the protein Tg, producing 3-iodotyrosine (MIT) and 3,5’- diiodotyrosine 
(DIT). Thirdly, TPO and H2O2 are further used to couple two DIT residues, or one MIT with 
one DIT residue, to produce T4 or T3 and rT3, respectively (Dunn & Dunn, 2001). 
Expression of TPO is regulated by the transcription factors TTF-1, TTF-2 and Pax-8. Estrogen 
stimulates TPO in addition to NIS in rats (Lima et al., 2006). The action of estradiol is 
variable and depends on the gonadal status and the age of the animal. 
Cancers with no iodide uptake contain approx. 30-fold less TPO and 20 fold less PDS (Mian et 
al., 2008). These TCs have a high frequency of BRAF mutation and 5-fold Glut-1 expression. 
TPO in TC is suppressed on the mRNA and on the protein level (Tanaka et al., 1996).  
4.4 Thyroglobulin (Tg) 
Tg is a large (660kD) dimeric protein, forming the main protein compound of the follicular 
colloid. Despite variable correlation of Tg levels and metastatic status, Tg mRNA in blood 
serves as a marker for TC and as follow-up of removed DTC. mRNA of Tg is significantly 
lower in TC and in adenoma and the decreases correlate to those in TSH-R mRNA. By 
contrast, mRNA of TPO showed no marked differences between normal and transformed 
thyroid tissues (Ohta et al., 1991). By other authors, levels of Tg mRNA varying from normal 
to complete loss in TC were reported (Brabant et al., 1991; Hoang-Vu et al., 1992) 
4.5 TSH-receptor (TSH-R) 
TSH and TSH-R are required for proliferation of thyrocytes and expression of differentiation 
markers like NIS (Garcia-Jimenez & Santisteban, 2007). The TSH-R is a 7-transmembrane 
spanning glycoprotein, also expressed in bone, brain, kidney, testes and cells of the immune 
system. In the extrathyroidal tissues its role is not clear (Matsumoto et al., 2008). TSH-R 
molecules are quite stable in the membrane and signalling occurs through TSH-binding. 
TSH activates the TSH-R and G-proteins such as GS-alpha at the surface of thyrocytes. 
Intracellular production of cyclic AMP by adenylyl cyclase stimulates the cAMP-dependent 
www.intechopen.com
 
Differentiation Therapy in Thyroid Carcinoma 
 
261 
protein kinase A, which in turn phosphorylates cytoplasmic and nuclear target proteins. 
One substrate is the nuclear transcription factor CREB, which activates the transcription of 
cAMP-responsive genes after being phosphorylated by PKA. TSH, at much higher levels, 
acts via phospholipase C and the phosphatidyl-inositol/Ca2+ signalling cascade with 
activation of protein kinase C (Hard, 1998). The cAMP pathway is functionally responsible 
for cell proliferation, iodide uptake, Tg and TPO expression, whereas the phosphatidyl-
inositol/Ca2+ signalling pathway stimulates generation of hydrogen peroxide and iodide 
efflux. Insulin and IGF-1 control TSH-R and Tg gene expression in rats and are necessary co-
factors for TSH in most species. Iodide, or the organic intermediate 2-iodohexadecanal, inhibits 
adenylate cyclase, TPO and NADPH oxidase. Another intermediate, the δ iodolactone 6-iodo-
5-hydroxy-8,11,14- eicosatrienoic acid inhibits specifically IP3 formation induced by growth 
factors. The receptor is hyperactivated in adenoma, less expressed in DTC and silenced in 
ATC. Inactivating mutations of the TSH-R have been reported in TC but appear not to be 
related to tumor onset but to be a marker of the ongoing de-differentiation. Activating 
mutations have been reported in some TC (Cetani et al., 1999,Esapa et al., 1997). Expression of 
TSH-R is similar in cancer and in thyroid adenoma tissues and the mRNA levels are only 
slightly decreased compared to normal thyroid tissue (Lazar et al., 1999). Reduced expression 
of TSH-R protein was seen only in high risk PTC (Tanaka et al., 1997) and low protein levels of 
TSH-R correlate with high proliferation (high Mib-1 index) in poorly differentiated TC 
(Matsumoto et al., 2008). TSH-R expression decreases to a lesser extent in cancer tissues than 
other thyroid-specific proteins like NIS, TPO and Tg. Defective TSH-R cAMP signalling in FTC 
thyroid cancer cell lines (Demeure et al., 1997) and impairment in signal transduction have 
been demonstrated in TC (Kimura et al., 1992) 
4.6 Molecular candidates for re-expression of thyroid-specific proteins 
Re-expression of thyroid-specific proteins in thyroid cancer is expected to increase iodide 
uptake and thereby increase the efficacy of radioiodine treatment. For the re-induction of 
thyroid-specific genes, the following nuclear targets are the most promising candidates: 
Retinoic acid receptors are crucial for the differentiation of tissues. Retinoids act as 
chemopreventive agents and increase differentiation in a variety of cancers. 
Peroxisome proliferator-activated receptor gamma (PPAR-) activation leads to activation 
of PTEN, which inhibits PI3K. DTCs show a decreased expression of this receptor, therefore 
PPAR- agonists may have a beneficial effect. 
Histone deacetylases and DNA methylases prevent transcription of genes linked to 
differentiation. Inhibitors of these enzymes may lead to re-differentiation. 
5. Compounds for re-differentiation 
5.1 Retinoids (RT) 
Retinoids, retinol and its derivatives, act on the nuclear receptors retinoic acid receptor 
(RAR) and retinoid X receptor (RXR). Retinoids are related to vitamin A and three 
generations of retinoids have been developed so far. First generation retinoids include 
retinol, retinal, retinoic acid (all-trans RA, 9-cis RA and 13-cis RA) and isoretinon, second 
generation retinoids were etretinate and acitretin and third generation retinoids comprise 
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tazarotene and bexarotene. The naturally occurring retinoids all-trans RA, 9-cis RA and 13-
cis RA are interconverted in vivo. Thyrocytes mainly express receptors for RAR- and  
RXR-. RXR- expression was reduced in the majority of poorly differentiated and 
anaplastic cell lines and tumor samples (Schmutzler et al., 1998). Retinoids can act through 
homodimers of retinoid receptors or as heterodimers of the RXR receptor with the PPAR- 
receptor (Figure 3). It is hypothesized that retinoids upregulate NIS expression mainly by 
activation of RAR (Kogai et al., 2004).  
 
Fig. 3. Retinoids bind to the RXR/PPAR- receptor dimer and this heterodimer binds to 
peroxisome proliferator response elements (PPRE). Subsequently, a co-activator, possessing 
histone acetylase activity, attaches to the complex (Co) and induces gene transcription.  
5.1.1 Compounds in clinical trials 
Retinoids increased expression of thyroid-specific proteins (Schreck et al., 1994; Schmutzler et 
al., 1997; Kurebayashi et al., 2000; Jeong et al., 2006) and increased iodide uptake (van Herle et 
al., 1990). As retinoids were already approved for other indications, clinical trials were 
initiated. Varying results were obtained with isotretinoin Accutane®, Roaccutane® (13-cis-
RA): iodide uptake was restored in 40% in the study by Simon et al. (Simon et al., 2002) but 
most other studies achieved much lower rates in the increase (Grunwald et al., 1998; Gruning 
et al., 2003; Kim et al., 2009). Similar inconsistent increases in iodide uptake were obtained by 
the use of tretinoin Vesanoid® (all-trans retinoic acid) and of Targretine® (bexarotene, Simon 
et al., 1996; Simon et al., 1998; Schmutzler & Kohrle, 2000; Simon et al., 2002; Coelho et al., 2004; 
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Short et al., 2004; Liu et al., 2006; Zhang et al., 2007). The expression of RAR- and RXR- could 
serve as an indicator for the response to RA treatment but based on existing studies, retinoids 
alone appear not to be an effective therapy for radioiodine-refractory thyroid cancer.  
5.1.2 Pre-clinical compounds  
9-cis RA and retinol were both less well studied for application in TC. 9-cis RA was shown 
to induce cell cycle arrest and re-expression of RAR- in TC cells (Fan et al., 2009) and 
retinol induced iodide uptake in differentiated cancer cell lines but had a low anti-
proliferative effect (Fröhlich et al., 2009). Although retinol, compared to RA, shows a lower 
rate of adverse effects (e.g. Fluhr et al., 1999), the different intracellular concentrations of the 
active metabolite due to variations in serum retinol binding protein, in cellular transport 
proteins and in the activity of intracellular dehydrogenases diminishes its suitability as drug 
candidate in the treatment of TC.  
5.2 Thiazolidinediones (TZDs) 
Peroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to 
the superfamily of nuclear receptors and related to the receptors for retinoic acid, estrogen, 
thyroid hormone, vitamin D and glucocorticoids. The three members of the PPAR family are 
PPAR-, PPAR-/ and PPAR-. All members regulate energy metabolism. PPAR- 
promotes differentiation of mesenchymal stem cells into adipocytes and osteoclasts and 
plays a role in tumorigenesis (Wan, 2010). Rearrangements of PPAR-/PAX-8 occur in 36% 
to 45.5% of FTC and in 37.5% of follicular variants of PTC (Nikiforova et al., 2003; Castro et 
al., 2006). The rearrangement induces inactivation of PPAR- function. PPAR agonists bind 
to PPAR- and form a heterodimer with the RXR receptor at the response elements, 
activating the transcription of target genes (Figure 4). PPAR- is involved in the 
differentiation of pre-adipocytes. Ligands of PPAR- inhibit growth in PTC cell lines (Ohta 
et al., 2001). The growth inhibiting effect is not correlated to the degree of expression of 
PPAR- suggesting that mechanisms independent from signalling through this receptor are 
involved in the differentiating action of PPAR- agonists (Klopper et al., 2004).  
5.2.1 Compounds in clinical trials 
Clinical studies with Avandia® (rosiglitazone) showed increased radioiodide uptake in 
therapeutic 131I scans (Kebebew et al., 2006; Tepmongkol et al., 2008). A current trial with 
rosiglitazone is ongoing and results are expected in the near future (www.clinicaltrial.gov). 
As PPAR- and RXRs form heterodimers there is the hope that, similar to results in other 
cancer types (Mehta et al., 2000), combinations of retinoids with TZDs may act 
synergistically. Based on data of an increased risk for cardiovascular events, however, the 
European Medicine Agency (EMA) has recommended in 9/2010 the withdrawl of all 
rosiglitazone-containing medications from the market.  
5.2.2 Pre-clinical compounds  
In vitro studies with troglitazone and rosiglitazone show that TZDs decrease proliferation 
and increase apoptosis and iodide uptake (Fröhlich et al., 2005). The anti-tumor effect of 
pioglitazone was much weaker than that of troglitazone and rosiglitazone. Also in primary 
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cultured ATC cells Actos® (pioglitazone) reduced proliferation to a lesser extent than 
rosiglitazone (Antonelli et al., 2009). Rezulin® (troglitazone) was the most effective 
compound regarding re-differentiation (Fröhlich et al., 2005) but its use in the treatment of 
TC is prevented by the withdrawal of the drug from the market due to severe liver toxicity. 
Another new agent, Ciglitazone induced decreased proliferation and increased apoptosis in 
a panel of TC cell lines with PPAR- expression (Martelli et al., 2002).  
5.3 Epigenetic alterations  
Epigenetic alterations are changes around the gene that alter gene expression. These changes 
include histone modifications and DNA methylation (Figure 4). Transcriptionally active 
chromatin regions are hyperacetylated and hypomethylated. Epigenetic alterations in tumor 
cells often result in silencing of genes involved in cell differentiation. Transcription factors 
generally act on un-methylated promoters at local sites where histones are acetylated. The 
silencing of a gene may result from the binding of methyl-binding proteins (e.g. MeCP2) to 
methylated cytosines, which recruits histone deacetylases (HDAC). Hyperacetylated histones 
activate a pre-programmed set of genes that leads to cell cycle arrest, differentiation and 
apoptosis (inhibition of tumor growth). HDAC inhibitors may contribute to the removal of 
MeCP2 from methylated cytosines and allow histone acetylase to re-acetylate histones at gene 
promoter. Hyperacetylated histones may recruit DNA demethylase and further provide  
 
Fig. 4. Epigenetic changes include addition of acetyl-groups (Ac) by the action of histone 
acetylase and methylation of DNA (M) by DNA methyltransferase. The multiprotein 
repressor complex binds predominantly at cytosine- and guanine- rich DNA regions and 
consists of methyl-CpG-binding protein 2 and mammalian transcriptional repressor mSin3 
and histone deacetylase (HDAC).  
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protection from DNA methylation. Inversely, demethylating agents can re-establish an active 
state by inducing the acetylation of histone. Via this mechanism inhibitiors of HDAC and of 
DNA methyltransferase could induce re-differentiation in thyroid cancer cells. 
5.3.1 Histone deacetylase inhibitors (HDI)  
In a nucleosome a DNA fragment is wrapped around a complex of histones (pair of H2A, 
H2B, H3 and H4). Acetylation occurs at lysine residues of the proteins. Deacetylation 
generates positively charged residues, which facilitate binding of histones to DNA leading 
to tightly packed chromatin. Thereby, binding to the promotor is prevented and gene 
transcription repressed (Xing, 2007). Genes silenced in TC include RAS, SF1A (signalling 
protein involved in RAS), tissue inhibitors of metalloproteinases, SLC5A8 (sodium coupled 
monocarboxylate transporter 1) as putative iodide transporter at the apical membrane), 
DARK (death associated protein kinase) and RAR-2.  
5.3.1.1 Compounds of HDI in clinical trials 
Suberoyl anile hydroxamic acid (SAHA, vorinostat [rINN]) is the most advanced compound 
of this group for treatment of TC. In ATC and DTC cell lines significant increases in NIS 
expression and decreased growth rates were recorded (Fortunati et al., 2004). In one clinical 
study evaluating SAHA, patients with metastatic TC were included. One out of five patients 
showed an improved iodide uptake (Kelly et al., 2005). Based on these promising results a 
phase II trial with SAHA, approved by the FDA as Zolinza®, was initiated. Medication 
resulted in slightly more patients with stable disease than with progressive disease (Woyach et 
al., 2008). In a phase II study romidepsin, a depsipeptide with the trade name Istodax® (FK 
228, FR 901228), restored radioiodine avidity in 2 of the 20 patients treated, but there were no 
objective responses even after 131I treatment (Sherman et al., 2009). A phase II study on the new 
hydroxamic acid derived histone deacetylase inhibitor panobinostat/panbinostat® (LBH589) 
is currently recruiting participants. The recruitment status of a phase II study on 
Depakene® (valproic acid) initiated in 2007, is unknown (http://www.clinicaltrials.gov).  
5.3.1.2 Pre-clinical compounds  
Encouraging results on differentiated and poorly differentiated thyroid carcinoma cell lines 
were also obtained with other HDIs.  
Trichostatin A® acted pro-apoptotic and increased NIS mRNA expression in TC cell lines 
(Puppin et al., 2005; Shen & Chung, 2005; Kondo et al., 2009). mRNA expression of PDS was 
reduced by trichostatin A treatment (Zarnegar et al., 2002). 
Entinostat® (SNDX275, MS 275) restored functional NIS activity in FTC and ATO cell lines 
20- 45 fold (Altmann et al., 2010). 
Phenylacetate (Ammonul®) increased iodide uptake and decreased secretion of Tg in two 
of the five evaluated TC cell lines (Kebebew et al., 1999). The inhibition of Tg secretion was 
interpreted as increase in intracellular accumulation of this protein. 
Apicidine and APHA compound 8 demonstrated a similar mode of action as valproic acid: 
all compounds strongly increased iodide-uptake with only a weak effect on proliferation 
(Fröhlich et al., 2009). 
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5.3.1.3 Combinations of HDIs with other compounds 
SAHA in combination with the mTOR inhibitor temsirolimus and the Akt and PI3K 
inhibitor perifosine showed a strong synergistic effect on NIS expression and on TSH 
receptor expression (Hou et al., 2010). The expression of the latter raised hope that the 
tumors would become responsive to TSH, which together with a functional NIS could 
enhance iodide uptake markedly. Other studies also suggested strong synergistic effects 
between HDIs and other compounds: ATRA in combination with tributyrin strongly 
enhanced NIS mRNA and protein expression and radioiodine uptake in FTC133 cells 
(Zhang et al., 2011). Although no increases were obtained in TSH-R and TPO mRNA 
expression upon combined treatment of vitamin D3 and SAHA, growth arrest was achieved 
in several poorly differentiated cells (Clinckspoor et al., 2011).  
5.3.2 Inhibitors of DNA methyltransferase (DMI) 
Upon DNA methylation CH3 groups are added to the fifth carbon position of the pyrimidine 
ring of cytosine residue in a CpG dinucleotide. CpG islands (regions rich in CpG 
dinucleotides) are usually located in the 5’ flanking promotor areas of genes. Gene promotor 
methylation near the transcription start site is usually associated with gene silencing (Xing, 
2007). Methylated cytosine residues are bound by methyl-binding proteins that 
subsequently recruit HDACs and histone methytransferases, forming a complex with 
mSin3, a mammalian transcriptional co-repressor. In thyroid carcinoma cells TTF-1, the key 
transcription factor for thyroid-specific genes (Tg, TPO, TSH-R, PDS and NIS), is silenced by 
hypermethylation.  
5.3.2.1 Compounds in clinical trials 
A phase II trial on Vidaza® (5-azacytidine) in metastatic TC has been completed and 
results will be published soon. A phase II study on Decitabine® (5-Aza-2’-deoxycytidine) 
is listed as ongoing clinical trial evaluating re-differentiation for TC 
(http://www.clinicaltrials.gov).  
5-Azacytidine was able to restore Tg expression in Ras-transfected TC lines (Avvedimento et 
al., 1989). In a study on mRNA expression of NIS, Tg, TPO and TSH-R and on iodide uptake 
in the PTC cell line B-CPAP, 5-Azacytidine compared to ATRA and trichostatin was very 
effective: it was the only compound, which increased iodide uptake (Tuncel et al., 2007). 
Also 5-Aza-2’-deoxycytidine increased differentiation and restored NIS expression in FTC, 
PTC and ATC cell lines (Kondo et al., 2009). 5-Aza-2’-deoxycytidine also induced mRNA 
expression of type I iodothyronine-5‘-deiodinase, another thyroid-specific protein (Mentrup 
et al., 2002 ).  
5.3.2.2 Combinations with other agents  
Combination with retinoids may increase the efficacy of the treatment because 5-Aza-2’-
deoxycytidine induced re-expression of the RAR- receptor (Miasaki et al., 2008). 5-
Azacytidine and RA together induced re-expression of differentiation-related proteins. In 
the human TC cell line FRO, TTF-1 and thyroglobulin were increased; in TT and WRO cell 
lines Pax-8 was increased; and in FRO and TT cell lines RAR-and NIS mRNA were 
increasedIodide uptake, however, was not increased and NIS localized in the cytoplasm 
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(Vivaldi et al., 2009). 5-Azacytidine and sodium butyrate increase NIS mRNA and iodide 
uptake in DRO cells. The NIS promotor region is often methylated and iodide-uptake 
apparently can be restored by the reversal of epigenetic changes (Venkataraman et al., 
1999). 
5.4 Other strategies for re-differentiation 
Several compounds have been investigated in a less systematic way for their action in TC. In 
this section, compounds, belonging to other classes but displaying positive effects on TC cell 
lines and in patients, are discussed. Since mRNA expression of NIS alone may not reflect 
protein levels and, even if the protein is expressed, it may not be correctly localized and not 
be functional, it is difficult to predict whether these compounds will have beneficial effects 
in clinical trials. 
5.4.1 Pre-clinical compounds  
5.4.1.1 Lovastatin ‘(e.g. Mevacor®) 
This inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase is used for lowering 
cholesterol in hypercholesterolemia to prevent cardiovascular disease. Inhibition of protein 
prenylation by lovastatin has anti-proliferative effects in normal and transformed thyrocytes 
(Bifulco et al., 1999) and reduced growth and invasion and caused re-differentiation in ATC 
cell lines by increasing Tg expression (Wang et al., 2003; Zhong et al., 2005). Lovastatin 
reduced proliferation but did not increase iodide uptake in cell lines derived from DTC 
(Fröhlich et al., 2009) and reduced the growth of ATCs in mouse xenografts (Wang et al., 
2010). 
5.4.1.2 1,25-dihydroxyvitamin D(3) (VitD3) ‘(e.g. Rocaltrol®) 
VitD3 acts through nuclear receptors expressed in most cell types. In addition to its main 
function on calcium and bone metabolism, the hormone also acts on proliferation, apoptosis 
and differentiation of cells. VitD3 appears to be a good target for cancer therapy because 
decreased levels have been demonstrated in breast, prostate and colon cancer. The situation 
in TC is not clear: whereas one study reported normal VitD3 levels in TC patients, another 
study reported decreased VitD3 levels in TC, though not in goiter patients (Laney et al., 
2010; Stepien et al., 2010). In cancers with proven deficiency VitD3 shows cytostatic effects 
and was tested successfully in a phase II clinical trial on prostate cancer (Srinivas & 
Feldman, 2009). VitD3 reduced tumor growth and increased differentiation (NIS and Tg 
mRNA) in vitro and in tumor xenografts (Drackiw et al. 2004; Okano et al. 1994; Akagi et al., 
2008). In combination with SAHA, VitD3 showed growth arrest but no effects on mRNA 
expression of TSH-R and of TPO in ATC cell lines (Clinckspoor et al., 2007).  
5.4.1.3 Arsenic trioxide (ATO) 
Clinical-grade ATO, Trisenox®, is used as second-line therapy in retinoic acid refractive 
acute promyelocytic leukemia (Shen et al., 1997). In the treatment of solid cancers, however 
ATO is not routinely used and only few clinical trials, like a phase II trial on hormone-
refractory prostate cancer, have been successfully performed (Gallagher et al., 2004). ATO 
acts by multiple mechanisms: depletion of glutathione, increase of reactive oxygen species, 
www.intechopen.com
 
Updates in the Understanding and Management of Thyroid Cancer 
 
268 
loss of mitochondrial potential and activation of caspase (Miller, 2002). Akt/protein kinase B 
pathway is also involved in the action. In several cell lines of differentiated TC the 
compounds reduced proliferation and increased apoptosis and iodide uptake (Fröhlich et 
al., 2008). Protein levels of NIS and PDS were not changed but in ATO-treated cells PDS 
displayed a polarized expression pattern. Depletion of glutathione increased the 
differentiating effect of ATO while Akt-inhibitors did not. Independent of the proliferation 
rate, ATO significantly decreased glucose uptake in TC cells as one additional mechanism of 
its multi-modal action.  
5.4.1.4 Gene therapy  
Transfection of TTF-1 and NIS together by an adenoviral vector into ATC cells achieved 
significant retention of iodide, whereas transfection with TTF-1 alone induced re-expression 
of TPO and Tg but not of NIS (Furuya et al., 2004). In extrathyroidal tissues, where no 
organification of iodide can occur, promising results were obtained. Re-circulation of iodide 
in the blood circulation of the liver results in high iodide-uptake rates and retention despite 
high efflux of iodide from the cells (Faivre et al., 2004). The successful introduction of 
functional and localized NIS was also demonstrated in dog prostate glands (Dwyer et al., 
2005). Stable transfection of thyroid cancer cells with Pax8 leads to recovery of iodide uptake 
(Presta et al., 2005) but transfection with TPO is not sufficient to restore iodide trapping in 
ATC cell lines (Haberkorn et al., 2001). 
5.4.1.5 Phosphatidylinositol-3-kinase inhibitors (PI3K inhibitors)/Akt-inhibitors  
These agents are used in the treatment of several solid cancers but efficacy has not been shown 
in in-vivo studies for TC. PI3K-inhibition increased functional expression of NIS in FRTL-5 and 
PTC cell lines (de Souza et al., 2010) and the PI3K inhibitor LY294002 increased iodide 
accumulation in TC lines (Furuya et al., 2007). In parallel to increased iodide uptake, this 
inhibitor increased the expression of PAX-8, suggesting a posttranslational stimulation effect 
on NIS (Kogai et al., 2008). In the same study the Akt1/Akt2 selective inhibitor Akti-1/2 
increased the expression of NIS-transfected TC cells not significantly. In non-transfected TC 
cell lines the re-differentiating effects of Akt inhibitor I (hydroxymethyl-chiro-inositol 2-(R)-2-
O- methyl-3-O-octadecylcarbonate) and Akt inhibitor V (triciribine) were small (Fröhlich et al., 
2008): the inhibitors showed an anti-proliferative effect but no increase in iodide uptake was 
seen. It appears that other Akt-inhibitors (e.g. KP372-1 and MK2206) also markedly reduce cell 
growth in various TC cell lines but have little effect on the expression of thyroid specific 
proteins (Mandal et al., 2005; Liu et al., 2011). Only in combination with MAPK inhibition Akt-
inhibitors significantly induced NIS mRNA expression in several TC cell lines (Hou et al., 2007). 
5.4.2 Compounds in clinical trials 
5.4.2.1 Lithium  
Eskalith®, Lithobid (lithium carbonate) is used in the treatment of manic depression and 
depressive disorders. It also causes an increased retention of iodide due to inhibition of the 
efflux of iodide leaving uptake of iodide unaffected (Temple et al., 1972). Despite causing an 
increase in radioiodine uptake, no beneficial effect was recorded in several studies on 
patients with metastatic DTC (Gershengorn et al., 1976; Pons et al., 1987; Koong et al., 1999; 
Liu et al., 2006). 
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5.4.2.2 Reverse transcriptase inhibitors 
Reverse transcriptase inhibitors like Sustiva® (efavirenz) and Viramune® (nevirapine) are 
part of the antiretroviral therapy for the treatment of human immunodeficiency virus type 1 
infection and AIDS. In addition, these compounds increase gene expression of TSH-R, 
thyroglobulin, TPO and NIS in the ATC lines (Landriscina et al., 2005). In a case report, up-
regulation of Tg and NIS was shown in a patient treated with nevirapine resulting in 
improved survival of the patient with PTC. (Modoni et al., 2007).  
6. Conclusion 
Although DTC is generally regarded as a less problematic tumor, metastatic DTC has a poor 
prognosis and is unresponsive to conventional treatments. Novel therapies include 
inhibitors of various growth factor tyrosine kinases and of kinases involved in dys-regulated 
intracellular signalling. In addition, re-expression of thyroid specific proteins, mainly NIS, 
by retinoids, PPAR- agonists as well as DNA methyltransferase and histone deacetylase 
inhibitors have potential as novel therapies.  
The TKIs sorafenib and sunitinib have entered clinical trials and appear to induce disease 
stabilization in treated patients. Differentiation therapy with retinoids did not live up to 
expected outcomes. The results of clinical trials with TZDs and HDIs are not yet known, 
though combination therapy with HDIs and conventional chemotherapy has shown 
promising early results. The final evaluation of these compounds is complicated by the fact 
that the achievement of stable disease cannot be regarded as a great success as many DTC 
do not progress rapidly any way. The inclusion of patients who only have progressive 
disease into clinical trials could enhance the clinical value of the induction of stable disease.  
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